Avience Biomedicals Limited (NSE:AVIENCE)
India · Delayed Price · Currency is INR 280.35
-5.50 (-1.92%)
At close: Jul 14, 2026
Avience Biomedicals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 452.36 | 239.64 | 109.21 | 101.48 | 11.33 |
Other Revenue | - | 0 | 0.06 | - | - |
| 452.36 | 239.64 | 109.26 | 101.48 | 11.33 | |
Revenue Growth (YoY) | 88.77% | 119.32% | 7.68% | 795.59% | - |
Cost of Revenue | 271.2 | 156.37 | 77.9 | 75.13 | 6 |
Gross Profit | 181.16 | 83.28 | 31.37 | 26.35 | 5.33 |
Selling, General & Admin | 46.19 | 27.36 | 11.68 | 6.65 | 1.3 |
Other Operating Expenses | 14.87 | 11.55 | 5.38 | 7.52 | 3.41 |
Operating Expenses | 69.65 | 45.08 | 19.15 | 15.14 | 4.79 |
Operating Income | 111.52 | 38.2 | 12.22 | 11.21 | 0.54 |
Interest Expense | -13.13 | -8.76 | -2.37 | -1.47 | -0.02 |
Interest & Investment Income | 0.38 | 0.33 | 0.07 | 0 | - |
Currency Exchange Gain (Loss) | 0.09 | -0.09 | - | 0.02 | -0 |
Other Non Operating Income (Expenses) | -0.38 | -0.32 | -0.33 | -0.14 | -0.1 |
EBT Excluding Unusual Items | 98.48 | 29.35 | 9.59 | 9.62 | 0.42 |
Gain (Loss) on Sale of Assets | -0.14 | 0.07 | - | - | - |
Other Unusual Items | 0.26 | 0.17 | - | - | 0.16 |
Pretax Income | 98.66 | 29.59 | 9.59 | 9.62 | 0.58 |
Income Tax Expense | 25.75 | 8.07 | 1.84 | 2.5 | 0.1 |
Net Income | 72.91 | 21.52 | 7.76 | 7.13 | 0.48 |
Net Income to Common | 72.91 | 21.52 | 7.76 | 7.13 | 0.48 |
Net Income Growth | 238.85% | 177.37% | 8.86% | 1394.08% | - |
Shares Outstanding (Basic) | 4 | 3 | 3 | 1 | 0 |
Shares Outstanding (Diluted) | 4 | 3 | 3 | 1 | 0 |
Shares Change (YoY) | 15.51% | 23.04% | 98.43% | 2046.71% | - |
EPS (Basic) | 19.22 | 6.55 | 2.91 | 5.30 | 7.61 |
EPS (Diluted) | 19.22 | 6.55 | 2.91 | 5.30 | 7.61 |
EPS Growth | 193.39% | 125.41% | -45.14% | -30.40% | - |
Free Cash Flow | -59.75 | -28.96 | -1.01 | -28.31 | -15.29 |
Free Cash Flow Per Share | -15.75 | -8.82 | -0.38 | -21.05 | -244.03 |
Gross Margin | 40.05% | 34.75% | 28.71% | 25.97% | 47.07% |
Operating Margin | 24.65% | 15.94% | 11.18% | 11.05% | 4.77% |
Profit Margin | 16.12% | 8.98% | 7.10% | 7.02% | 4.21% |
Free Cash Flow Margin | -13.21% | -12.08% | -0.92% | -27.90% | -134.97% |
EBITDA | 120.11 | 44.36 | 14.31 | 12.18 | 0.62 |
EBITDA Margin | 26.55% | 18.51% | 13.10% | 12.00% | 5.50% |
D&A For EBITDA | 8.59 | 6.17 | 2.09 | 0.97 | 0.08 |
EBIT | 111.52 | 38.2 | 12.22 | 11.21 | 0.54 |
EBIT Margin | 24.65% | 15.94% | 11.18% | 11.05% | 4.77% |
Effective Tax Rate | 26.10% | 27.28% | 19.13% | 25.94% | 17.28% |
Revenue as Reported | 459.67 | 243.73 | 109.34 | 101.49 | 11.49 |
Advertising Expenses | 10.13 | 4.09 | 2.66 | 0.08 | 0.06 |